Harrow, Inc. Revenues
Harrow, Inc. (HROW) reported Revenues of $10.38 million for the 3-month period ending 2018-06-30, per its 10-Q filed 2018-08-06.
Discontinued › Income Statement › Revenue
us-gaap:Revenues · last filed 2018-08-06
- Harrow, Inc. revenues for the quarter ending 2018-06-30 was $10.38M, a 51.44% increase year-over-year.
- Harrow, Inc. revenues for the quarter ending 2017-06-30 was $6.86M.
| Period end | Revenues 3 month | Revenues 6 month |
|---|---|---|
| 2018-06-30 | $10.38M 10-Q · filed 2018-08-06 | $19.25M 10-Q · filed 2018-08-06 |
| 2017-06-30 | $6.86M 10-Q · filed 2018-08-06 | $12.95M 10-Q · filed 2018-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |